FUNDING

 

Belgian

Vrije Universiteit Brussel
  • Elucidation of the role of connexin proteins in hepatocyte apoptosis

2008-2009: 10.000€

Promoter: Mathieu Vinken

Co-promoter: Vera Rogiers

  • Connexin signaling research group (Alliance Research Group)

2011-2020: 10.000€

Promoters: Mathieu Vinken, Luc Leybaert

  • Liver-based in vitro models for toxicity testing and translational aspects (Strategic Research Program)

2014-2019: 450.000€

Promoter: Vera Rogiers

Co-promoters: Tamara Vanhaecke, Mathieu Vinken, Jan Gutermuth

  • Liver connexin and pannexin research group (Alliance Research Group)

2014-2023: 90.000€

Promoters: Mathieu Vinken, Bruno Cogliati

  • Panx1 as a novel biomarker for non-alcoholic steatohepatitis (Industrial Research Fund)

2016-2017: 50.000€

Promoter: Mathieu Vinken

Co-promoter: Serge Muyldermans

  • Exploiting peptides: protein binders, modulators and inhibitors for imaging and therapy (Strategic Research Program)

2019-2023: 1.220.000€

Promoter: Steven Ballet

Co-promoters: Vicky Caveliers, Sophie Hernot, Wim Versées, Mathieu Vinken, Serge Muyldermans, Nick Devoogdt

  • Non-animal methodologies for toxicity testing of chemical compounds (Interdisciplinary Research Program)

2019-2023: 550.000€

Promoter: Tamara Vanhaecke

Co-promoters: Mathieu Vinken, Joery De Kock, Olga De Troyer, Paul Quinn

  • B-liver: The Brussels liver research to valorisation alliance (Groups of Expertise in Applied Research Program)

2020-2024: 650.000€

Promoter: Tamara Vanhaecke

Co-promoters: Leo van Grunsven, Joery De Kock, Mathieu Vinken, Hendrik Reynaert

Scientific Fund Willy Gepts
  • Connexin hemichannels as drug targets in acute liver failure: a combined in vitro-in vivo study

2012-2016: 25.000€

Promoter: Mathieu Vinken

Co-promoters: Tamara Vanhaecke, Vera Rogiers

  • Hemichannels as novel pharmacological targets and biomarkers of cholestasis

2017-2020: 25.000€

Promoter: Mathieu Vinken

Co-promoters: Michaël Maes, Bruno Cogliati

  • Are connexins, pannexins and their (hemi)channels novel biomarkers and pharmacological targets in the prognosis and therapy of liver cancer?

2020-2023: 22.500€

Promoter: Mathieu Vinken

Co-promoters: Kaat Leroy, Bruno Cogliati

Innoviris

     ONTOX: ontology-driven and artificial intelligence-based repeated dose toxicity testing of chemical for next    

     generation risk assessment

2019: 25.000€

Promoter: Mathieu Vinken

Research Foundation Flanders
  • Role of Cx32 and Cx43 in the control of hepatocellular homeostasis: development of a long-term primary hepatocyte culture system for pharmaco-toxicological studies

2010-2011: 16.400€

Promoter: Mathieu Vinken

Co-promoter: Vera Rogiers

  • Connexin and pannexin channels: regulation, functions and applications

2010-2019: 120.000€

Promoter: Luc Leybaert

Co-promoters: Geert Bultynck, Mathieu Vinken

  • Hepatocyte-like cells derived from adult human skin progenitor cells as a potential in vitro model for the screening of drugs for liver toxicity

2013-2016: 160.000€

Promoter: Tamara Vanhaecke

Co-promoters: Mathieu Vinken, Vera Rogiers

  • Characterization of Cx43- and Panx1-based hemichannels as tissue biomarkers and pharmacological targets in acute liver failure

2014-2017: 275.236€

Promoter: Mathieu Vinken

Co-promoters: Tamara Vanhaecke, Vera Rogiers

  • Hemichannels as novel pharmacological targets in liver fibrosis

2014-2017: 360.000€

Promoter: Mathieu Vinken

Co-promoters: Elke Decrock, Luc Leybaert, Tamara Vanhaecke, Vera Rogiers

  • Are connexin and pannexin hemichannels therapeutic drug targets and diagnostic biomarkers in cholestasis?

2018-2021: 425.700€

Promoter: Mathieu Vinken

Co-promoter: Pieter Annaert

  • Nanobody-based inhibitors of connexin and pannexin hemichannels as therapeutics for the treatment of hepatic and cardiovascular diseases

2018-2021: 457.700€

Promoter: Mathieu Vinken

Co-promoters: Serge Muyldermans, Brenda Kwak

  • Light sheet fluorescence microscope in life sciences and medical research

2018-2022: 689.653,84€

Promoter: Karen Sermon

Co-promoters: Hilde Van De Velde, Ellen Goossens, Luc Baeyens, Jo Van Ginderachter, Dimitri De Bundel, Sophie Hernot, Joery De Kock, Mathieu Vinken, Tamara Vanhaecke, Robim Marcelino Rodrigues, Leo van Grunsven

  • Are connexins, pannexins and their (hemi)channels novel biomarkers and pharmacological targets in the prognosis and therapy of liver cancer?

2019-2021: 225.000€ (+ 300.000BRL from São Paulo Research Foundation)

Promoters: Mathieu Vinken, Bruno Cogliati

  • Seahorse platform: the Agilent Seahorse Flux Analyser with integrated normalization system

2020-2023: 342.415,45€

Promoter: Ann Massie

Co-promoters: Eline Menu, Mathieu Vinken, Jo Van Ginderachter, Claudia Spits, Johan Stiens, Rose Njemini, Kenno Vanommeslaeghe

European 

 
6th and 7th Framework Program: Societal Challenges
  • CarcinoGENOMICS: development of a high throughput genomics-based test for assessing genotoxic and carcinogenic properties of chemical compounds in vitro

2006-2011: 12.619.013€ (539.923€ for Vrije Universiteit Brussel)

Promoter: Jos Kleinjans

Co-promoters at Vrije Universiteit Brussel: Vera Rogiers, Mathieu Vinken, Tamara Vanhaecke

  • DETECTIVE: detection of endpoints and biomarkers of repeated dose toxicity using in vitro systems

2011-2015: 8.674.850,6€ (710.567€ for Vrije Universiteit Brussel)

Promoter: Jürgen Hescheler

Co-promoters at Vrije Universiteit Brussel: Vera Rogiers, Mathieu Vinken, Tamara Vanhaecke

  • HeMiBio: hepatic microfluidic bioreactor

2011-2015: 9.400.000€ (561.942€ for Vrije Universiteit Brussel)

Promoter: Catherine Verfaillie

Co-promoters at Vrije Universiteit Brussel: Vera Rogiers, Mathieu Vinken, Tamara Vanhaecke

7th Framework Program and Horizon2020: European Research Council
  • CONNECT: connexin and pannexin channels as drug targets and biomarkers in acute and chronic liver disease (Starting Grant)

2014-2019: 1.473.928,8€

Promoter: Mathieu Vinken

  • CONNECT-2-CLINIC: pannexin nanobodies for the clinical treatment of liver disease (Proof-of-Concept Grant)

2020-2021: 150.000€

Promoter: Mathieu Vinken

Horizon2020: Future and Emerging Technologies
  • PANACHE: production of next generation modulators of pannexins and connexins as novel therapeutics in the treatment of inflammatory cardiovascular, hepatic and joint diseases (FETopen)

2020-2024: 3.503.628,75€

Promoter: Mathieu Vinken

Co-promoters: Steven Ballet, Brenda Kwak, Maria Mayan, Rafael Gozalbes

Horizon2020: Marie Skłodowska-Curie Actions
  • In3: an integrated interdisciplinary approach to animal-free chemical and nanomaterial safety assessment (Innovative Training Network)

2017-2020: 3.861.963€

Promoter: Paul Jennings

Partner organization: European Society of Toxicology In Vitro (Mathieu Vinken)

  • ChOLLATERAL: generation of an adverse outcome pathway network on cholestatic liver injury for mechanism-based in vitro testing the toxicity induced by chemicals (Individual Fellowship)

2019-2021: 178.300€ individual fellowship to Vânia Vilas-Boas (+ 19.200€)

Promoter: Vânia Vilas-Boas

Supervisor: Mathieu Vinken

Cosmetics Europe
  • Development and testing of a repeated dose toxicity ontology model for chemical risk assessment purposes: liver effects as a case study

2018-2021: 906.386€ (324.000€ for Vrije Universiteit Brussel)

Promoter: Mathieu Vinken

Co-promoters: Aldert Piersma, Bob van de Water, Mark Cronin, Nynke Kramer, Dinant Kroese, George Daston, Chihae Yang

Brazilian

 
Universidade de São Paulo
  • Connexin and pannexin channels as drug targets and biomarkers in acute and chronic liver disease

2014-2016: 163.200BRL

Promoter: Mathieu Vinken

São Paulo Research Foundation
  • Connexins and pannexins as drug targets and biomarkers in liver disease

2014-2017: 2.373.910BRL

Promoter: Mathieu Vinken

Co-promoter: Bruno Cogliati

 

USA

Center for Alternatives to Animal Testing
  • Establishment and in vitro testing of an adverse outcome pathway of cholestatic liver injury

2018-2020: 40.000$

Promoter: Mathieu Vinken